Your session is about to expire
← Back to Search
Gallium-68 citrate, PET for Prostate Cancer
Study Summary
This trial is investigating the use of gallium-68 citrate PET in patients with metastatic castration-resistant prostate cancer who are planning to undergo a metastatic tumor biopsy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does this clinical trial still have availability for prospective participants?
"This medical trial, whose initial post date was May 28th 2015 and last update on June 22nd 2022, is currently closed to new participants. Nevertheless, 1260 additional trials are accepting patients as of now."
What is the main purpose of this investigation?
"This medical trial will primarily assess SUVmax-ave over a single day period. Additionally, they are measuring the sensitivity of gallium citrate PET in comparison to bone scans; correlating SUVax and MYC gene expression for patients that opt into biopsy procedures; along with evaluating the specificity of gallium citrate PET against its counterpart imaging technique."
How many participants is this medical experiment enlisting?
"Unfortunately, this experiment has concluded its participant recruitment. According to the information made available on clinicaltrials.gov, the trial was first listed May 28th 2015 and last updated June 22nd 2022. For those seeking similar studies, there are currently 1252 prostate cancer trials open for enrollment as well 8 Gallium-68 citrate PET investigations searching for volunteers."
What conditions are often evaluated with Gallium-68 citrate PET scans?
"Gallium-68 citrate PET is a viable method of managing the symptoms associated with metabolic acidosis, calcinosis, and heartburn."
Share this study with friends
Copy Link
Messenger